FDA Warning Letter Statistics 2013 Regarding Process Validation/Qualification/Calibration
In 2013, process validation was at the top of the critised deviations. Missing or insufficient process validation was quoted 15 times. The most frequent critics were made to dosage forms (five times) and the manufacture of creams (three times).
The non-existent validation of a filtration time and of a filter replacement, as well as insufficient packaging validation (filling, sealing and labelling) have been criticised too. More and more terms from the 'new' FDA Guidance of 2011 appear among the corrective measures; for example "control strategy" and "scientific evidence that your manufacturing process are capable of consistently manufacturing quality products" are required.
Deviations regarding missing or insufficient cleaning validation have been observed seven times; more precisely: the non-existent use of worst case products, handling errors in "swabbing" and missing swab recovery rates were observed and criticised.
Media fills have also been often criticised (four times). Missing hold times of vials before incubation, missing rational numbers for the non-incubating of filled vials, no documentation about the reasons for rejecting vials, and insufficient failure investigation were among the points of criticism. Interestingly, the (non-validated) hold time was necessary as the company hadn't enough resources to evaluate the media fills.
Deficiencies of qualification in manufacturing were identified 11 times and concerned (five times) missing "smoke studies" for clean room qualification: the insufficient qualification of a water facility and poor clean room design were respectively criticised once. An expired balance calibration was observed once.
Also one observation was made regarding the lack of validation for the computer software Microsoft Dynamics.
Conclusion: The analysis is similar to that of the previous years and the top deficiencies haven't changed that much. Most findings concerned process validation, and again, the majority had to do with solid forms. The number of insufficient media fills was also comparable to that of the previous years. Nevertheless, the increase of qualification deficiencies — whereby also in the past, missing or poor "smoke studies" often appeared — is apparent.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...